Dr. Eric Wang received his Bachelor of Science degree in Pharmacy from the School of Pharmaceutical Sciences at Peking University in Beijing, China. He earned his PhD in Pharmaceutical Sciences from the University of Texas at Austin. Following his PhD, he underwent postdoctoral training at the U.S. Army Institute of Surgical Research in San Antonio, Texas. Dr. Wang joined PCOM in 2010 and has since been a foundational member of the faculty, primarily teaching courses related to pharmaceutics and pharmacology, such as Biopharmaceutics, Pharmacokinetics, Pharmaceutical Compounding, Pharmaceutical Calculation, and pharmacology of medications in various diseases. His dedication to developing a rigorous and effective curriculum has been instrumental in improving student learning outcomes.
In his role as an educator, Dr. Wang has received numerous accolades, including being named Teacher of the Year four times (2019, 2021, 2022, and 2023) by his students. His mentorship extends beyond the classroom, guiding PharmD, DO, and Biomedical Science Thesis students through their research projects and presentations at local and national scientific meetings. His commitment to student success is evident in the numerous awards his mentees have received for their research posters at PCOM Research Day events.
Dr. Wang’s research interests focus on drug discovery and development, particularly in identifying compounds with anti-cancer, anti-inflammatory, and antioxidant properties. His recent work has explored the inhibitory effects of natural compounds on multiple myeloma, a type of plasma cell cancer. This research has garnered recognition, including the American Association of Colleges of Pharmacy (AACP) New Investigator Award in 2016. He has published extensively in peer-reviewed journals and presented his findings at various national and international conferences.
In addition to his teaching and research responsibilities, Dr. Wang has been an active participant in numerous committees at PCOM, including curriculum, assessment, admissions, scholarship and awards, faculty development, and faculty search committees. He played a crucial role in the ACPE accreditation process and contributed to the success of the School of Pharmacy’s accreditation and site visits. Dr. Wang also serves as a guest editor for several peer-reviewed journals and a reviewer for various grants and scholarly publications. He is involved in faculty development initiatives, particularly supporting virtual teaching during the COVID-19 pandemic. His multifaceted contributions have significantly advanced the academic and research missions of PCOM.
Role: Principal Investigator
Award type: External funding from pharmaceutical industry
Funding Agency: Aurinia Pharmaceuticals
Title: Comparing the Effects of Voclosporin, Cyclosporin A and Tacrolimus on Calcineurin
Isoform Activity and Mediators of Fibrosis in Kidney Cells In Vitro
Duration: 08/1/2021-07/30/2023
Role: Co-Principal Investigator
Award type: The Community-Based Research Faculty Fellowship
Funding Agency: PCOM Alumni Association
Title: Impact of Implementing Medication Therapy Management Service for Underserved
Populations Children with Disabilities
Duration: 03/2022 - 02/2023
Role: Principal Investigator
Award type: Internal funding for MS-Thesis of Biomed students
Funding Agency: PCOM Division of Research
Title: Preparation of xanthohumol (XN)-incorporated iron oxide nanoparticles and their
inhibitory effects on multiple myeloma cell growth
Duration: 07/1/2021-06/30/2022
Role: Principal Investigator
Award type: Internal funding for MS-Thesis of Biomed students
Funding Agency: PCOM Division of Research
Title: Preparation of caffeic acid phenethyl ester (CAPE)-incorporated nanoparticles
and their inhibitory effects on multiple myeloma cell growth
Duration: 07/1/2020-06/30/2021
Role: Principal Investigator
Award type: Internal funding for MS-Thesis of Biomed students
Funding Agency: PCOM Division of Research
Title: Anti-myeloma effect of xanthohumol, a prenylated flavonoid from hops plant
Duration: 07/1/2019-06/30/2020
Role: Principal Investigator
Award type: Internal funding
Funding Agency: PCOM Division of Research
Title: Preparation of caffeic acid phenethyl ester (CAPE)-incorporated nanoparticles
and their inhibitory effects on multiple myeloma cell growth
Duration: 07/1/2019-06/30/2020
Role: Principal Investigator
Award type: Internal funding for MS-Thesis of Biomed students
Funding Agency: PCOM Division of Research
Title: Anti-myeloma effect and structure activity relationship of caffeic acid phenethyl
ester on multiple myeloma
Duration: 07/1/2018-06/30/2019
Role: Principal Investigator
Award type: Internal funding for MS-Thesis of Biomed students
Funding Agency: PCOM Chief Research and Scientific Officer (CRSO)-funding
Title: Anti-myeloma effect of imidazole and methyl derivatives of a synthetic oleanane
triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO)
Duration: 07/1/2017-06/30/2018
Role: Principal Investigator
Award type: Internal funding for MS-Thesis of Biomed students
Funding Agency: PCOM Chief Research and Scientific Officer (CRSO)-funding
Title: Effects of caffeic acid phenethyl ester (CAPE) and its derivatives on human
hepatic cancer cells
Duration: 07/1/2017-06/30/2018
Role: Principal Investigator
Award type: New Investigator Award
Funding source: American Association of Colleges of Pharmacy
Title: Anti-Myeloma Effect of Caffeic Acid Phenethyl Ester: The Role of Oxidative
Stress
Duration: 1/1/2016-12/31/2016
Role: Principal Investigator
Award type: Internal funding for MS-Thesis of Biomed students
Funding Agency: PCOM Chief Research and Scientific Officer (CRSO)-funding
Title: Anti-Myeloma Effect of a Novel Derivative of Caffeic Acid Phenethyl Ester (FCAPE)
Duration: 07/1/2016-06/30/2017
Role: Principal investigator
Award type: Internal funding
Funding Agency: PCOM CSO-funding
Title: Attenuation of immune-complex mediated inflammation through inhibition of NF-κB
activation by caffeic acid phenethyl ester (CAPE)
Duration: 12/17/2013-11/30/2015
Role: Principal investigator
Award type: Internal funding
Funding Agency: PCOM Center for Chronic Disorders of Aging (CCDA)-funding
Title: Inhibitory effects of caffeic acid phenethyl ester on multiple myeloma cell
growth: Nrf2 and NF-κB crosstalk
Duration: 08/01/2013-07/30/2014
Role: Principal investigator
Award type: Internal funding
Funding Agency: PCOM CCDA-funding
Title: Inhibitory effects of caffeic acid phenethyl ester on multiple myeloma cell
growth
Duration: 08/01/2012-07/30/2013
Role: Principal investigator
Award type: Internal funding
Funding Agency: PCOM CCDA-funding
Title: Identification of potential drug candidates for ameliorating oxidative stress
involved ischemia reperfusion injury
Duration: 08/01/2011-07/30/2012
Biopharmaceutics
Pharmacokinetics
Pharmaceutics
Pharmaceutics Compounding Lab
Pharmaceutical Calculations
Dr. Eric Wang’s research interest is focused on the drug discovery and development to identify potential drug candidates with anti-cancer, anti-inflammatory, and anti-oxidant properties. Currently, he is investigating the effects of potential drug candidates from natural sources for the treatment of multiple myeloma, a cancer of plasma cells in the bone marrow. This disease remains incurable and results in 10 to 15 % of blood cancer and 20% human death related to blood and bone marrow cancer. His research is funded through PCOM intramural grants and supported by American Association of Colleges of Pharmacy (AACP) as he is the recipient of AACP New Investigator Award 2016. He has presented his research in various national and international conferences and published peer-reviewed articles in different pharmaceutical fields including medicinal chemistry, molecular pharmacology, pharmaceutical analysis and pharmacokinetics.
American Association of Pharmaceutical Scientists
American Association of Advancement of Science
American Association of Colleges of Pharmacy
American Society for Pharmacology and Experimental Therapeutics
International Society for the Study of Xenobiotics
© 2024 Philadelphia College of Osteopathic Medicine